Communication of Treatment Options for High-Risk NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

Now Viewing

EP: 10.Communication of Treatment Options for High-Risk NMIBC

EP: 11.Checkpoint Inhibitors for Treatment of NMIBC

Video content above is prompted by the following:

How do you communicate various options for NMIBC with patients and healthcare professionals?

Related Videos

Resective Surgery and Minimally Invasive Procedures For BPH

Checkpoint Inhibitors for Treatment of NMIBC

Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

BPH: The Patient Journey

Addressing Remaining Unmet Needs in mCRPC

Use and Sequencing of Novel Treatments in NMIBC

The DORA Trial

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC